CABOSEQ: The efficacy of cabozantinib post upfront immuno-oncology combinations in patients with advanced renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

JOURNAL OF CLINICAL ONCOLOGY(2022)

引用 5|浏览5
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要